Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX110 Infusion for Recurrent Medulloblastoma
NCT04315064Phase 1Completed
- Sponsor
- UTHealth Houston
- Start
- Apr 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of panobinostat in medulloblastoma, sponsored by UTHealth Houston. Primary endpoint: Number of participants with grade 3 through grade 5 new neurological adverse events that are related to study drug. Started Apr 2020; status: completed.
02
Drugs
panobinostat
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT04315064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315064.